DE69212710T2 - Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften - Google Patents

Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften

Info

Publication number
DE69212710T2
DE69212710T2 DE69212710T DE69212710T DE69212710T2 DE 69212710 T2 DE69212710 T2 DE 69212710T2 DE 69212710 T DE69212710 T DE 69212710T DE 69212710 T DE69212710 T DE 69212710T DE 69212710 T2 DE69212710 T2 DE 69212710T2
Authority
DE
Germany
Prior art keywords
composition
pharmaceutical composition
controlled release
release
bioadhesive properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69212710T
Other languages
English (en)
Other versions
DE69212710D1 (de
Inventor
Giancarlo Santus
Giuseppe Bottoni
Giovanni Sala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recordati SA
Original Assignee
Recordati SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati SA filed Critical Recordati SA
Publication of DE69212710D1 publication Critical patent/DE69212710D1/de
Application granted granted Critical
Publication of DE69212710T2 publication Critical patent/DE69212710T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089Processes
DE69212710T 1991-05-30 1992-05-29 Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften Expired - Fee Related DE69212710T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911486A IT1250421B (it) 1991-05-30 1991-05-30 Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.

Publications (2)

Publication Number Publication Date
DE69212710D1 DE69212710D1 (de) 1996-09-19
DE69212710T2 true DE69212710T2 (de) 1996-12-19

Family

ID=11360019

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69212710T Expired - Fee Related DE69212710T2 (de) 1991-05-30 1992-05-29 Pharmazeutische Zusammensetzung mit kontrollierter Freigabe und bioadhäsiven Eigenschaften

Country Status (9)

Country Link
US (1) US5472704A (de)
EP (1) EP0516141B1 (de)
JP (1) JPH07215843A (de)
AT (1) ATE141159T1 (de)
DE (1) DE69212710T2 (de)
DK (1) DK0516141T3 (de)
ES (1) ES2091363T3 (de)
GR (1) GR3020813T3 (de)
IT (1) IT1250421B (de)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985249A (en) 1990-03-22 1999-11-16 Ultradent Products, Inc. Sticky dental compositions for adhering a passive-type dental tray over a person's teeth
US6036943A (en) 1990-03-22 2000-03-14 Ultradent Products, Inc. Methods for treating a person's teeth using sticky dental compositions in combination with passive-type dental trays
US5571533A (en) * 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
DK0797988T3 (da) 1993-07-19 2009-05-11 Univ British Columbia Anti-angiogene præparater og fremgangsmåder til anvendelse deraf
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
DE4404011A1 (de) * 1994-02-09 1995-08-10 Jenapharm Gmbh Neue, adhäsiv wirkende Zubereitungen für mit Flüssigkeit benetzte Oberflächen, Verfahren und Vorrichtung zur Erfassung der Adhäsionszeit diesbezüglicher Zubereitungen
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US7091008B1 (en) 1994-07-01 2006-08-15 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase genes and expression thereof in Bacillus hosts
US6455304B1 (en) * 1994-07-01 2002-09-24 The Board Of Regents Of The University Of Oklahoma Hyaluronate synthase gene and uses thereof
IT1273742B (it) * 1994-08-01 1997-07-09 Lifegroup Spa Composizioni ad elevata bioadesivita' e mucoadesivita' utili per il trattamento di epitali e mucose
WO1996021432A1 (en) * 1995-01-11 1996-07-18 Cygnus, Inc. Delivery of active substances by way of mucosal surfaces of pharyngeal and esophageal regions
EP0812195B1 (de) * 1995-02-28 2002-10-30 Aventis Pharmaceuticals Inc. Arzneizubereitungen für piperidinalkanolderivate
US6992107B1 (en) * 1995-03-10 2006-01-31 Photocure Asa Esters of 5-aminolevulinic acid and their use as photosensitizing compounds in photochemotherapy
FR2737661B1 (fr) * 1995-08-08 1997-10-31 Mgi Pharma Inc Composition pharmaceutique sous forme de comprimes comprenant du chlorhydrate de pilocarpine
US5741525A (en) * 1995-10-24 1998-04-21 Marshall University Research Corporation Vaginal pharmaceutical hydrogen peroxide composition
DE19600324A1 (de) * 1996-01-08 1997-07-10 Basf Ag Granulate für kosmetische und pharmazeutische Zubereitungen
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
US20020018754A1 (en) 1999-03-15 2002-02-14 Paul Albert Sagel Shapes for tooth whitening strips
US6582708B1 (en) 2000-06-28 2003-06-24 The Procter & Gamble Company Tooth whitening substance
US6096328A (en) 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
PT998272E (pt) * 1997-08-26 2003-09-30 Aventis Pharma Inc Composicao farmaceutica para combinacao do descongestionante piperidinoalcanol
CN1322121C (zh) * 1997-10-31 2007-06-20 俄克拉何马大学董事会 透明质酸合酶基因及其应用
CN101113436B (zh) * 1997-10-31 2013-02-06 俄克拉何马大学董事会 透明质酸合酶基因及其应用
JPH11269064A (ja) * 1998-03-20 1999-10-05 Kowa Co 胃・十二指腸付着性医薬組成物
US20060188966A1 (en) * 1998-04-02 2006-08-24 Deangelis Paul L Natural, chimeric and hybrid glycosaminoglycan polymers and methods of making and using same
US7060469B2 (en) * 1998-04-02 2006-06-13 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
US20080108110A1 (en) * 1998-04-02 2008-05-08 Deangelis Paul L Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US6987023B2 (en) * 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US7223571B2 (en) * 1998-04-02 2007-05-29 The Board Of Regents Of The Universtiy Of Oklahoma Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US7094581B2 (en) * 1998-10-26 2006-08-22 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthases and methods of making and using same
EP1129209B1 (de) * 1998-11-11 2009-01-21 The Board Of Regents Of The University Of Oklahoma Polymerpfropfung mittels polysaccharide-synthase
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
IN191482B (de) * 1999-03-19 2003-12-06 Ranbaxy Lab Ltd
US7642071B2 (en) 1999-04-01 2010-01-05 The Board Of Regents Of The University Of Oklahoma Methods of expressing gram-negative glycosaminoglycan synthase genes in gram-positive hosts
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
EP1200064B1 (de) 1999-07-02 2003-05-02 The Procter & Gamble Company Zusammensetzungen zur freisetzung von mundpflegewirkstoffen enthaltend organosiloxan harze durch verwendung eines wiederablösbaren trägerstreifens
EP1206943B1 (de) 1999-08-26 2010-04-07 Takeda Pharmaceutical Company Limited Nasenschleimhaut haftende matrix
US7534589B2 (en) * 1999-11-10 2009-05-19 The Board Of Regents Of The University Of Oklahoma Polymer grafting by polysaccharide synthases
AU2001234005B2 (en) * 2000-02-28 2006-01-19 Pharmakodex Limited Improvements in or relating to the delivery of oral drugs
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6372252B1 (en) 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
CN1311800C (zh) 2000-06-28 2007-04-25 宝洁公司 提高活性过氧化物的稳定性的结构体和组合物
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
US7803392B2 (en) * 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
DE10107659B4 (de) * 2001-02-19 2008-03-13 Lts Lohmann Therapie-Systeme Ag Mucoadhäsive zerfallsfähige Arzneizubereitung zur Wirkstoffverabreichung in der Veterinär- und Humanmedizin
DE10120092B4 (de) * 2001-04-25 2008-03-20 Lts Lohmann Therapie-Systeme Ag Magensaftresistente Vorrichtung zur Freisetzung von mukoadhäsiven Wirkstoffträgern und Verfahren zur Herstellung der magensaftresistenten Vorrichtung
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7910641B2 (en) 2001-10-12 2011-03-22 Monosol Rx, Llc PH modulated films for delivery of actives
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8663687B2 (en) 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20030114394A1 (en) * 2001-10-29 2003-06-19 Levine Howard L. Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
EP1864660B1 (de) 2001-11-01 2010-12-29 Spectrum Pharmaceuticals, Inc. Medizinische Zusammensetzungen zur intravesikalen Behandlung von Blasenkrebs
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US20070020737A1 (en) * 2001-12-03 2007-01-25 Pummill Philip E Hyaluronan synthases and methods of making and using same
MXPA04006017A (es) * 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
WO2003105811A2 (en) * 2002-01-31 2003-12-24 Southwest Research Institute Controlled release compositions and methods for using same
BG65734B1 (bg) * 2002-02-22 2009-09-30 Био Терапютикс - Еоод Течен мукоадхезивен фармацевтичен състав
US8728510B1 (en) 2002-03-15 2014-05-20 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing a bioadhesive material
WO2003084517A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
US8017150B2 (en) 2002-04-11 2011-09-13 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US6949240B2 (en) 2002-05-23 2005-09-27 The Procter & Gamble Company Tooth whitening products
US8268352B2 (en) * 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) * 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US8524200B2 (en) 2002-09-11 2013-09-03 The Procter & Gamble Company Tooth whitening products
US20040115137A1 (en) * 2002-12-17 2004-06-17 Verrall Andrew P. Water-soluble film for oral administration
US20040228918A1 (en) * 2003-01-02 2004-11-18 Chih-Ming Chen Granule modulating hydrogel system
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー, インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
DE10300325A1 (de) * 2003-01-09 2004-07-22 Hexal Ag Granulat mit öliger Substanz, Herstellungsverfahren und Tablette
US20050118261A1 (en) * 2003-06-12 2005-06-02 Oien Hal J. Compositions and methods of administering doxepin to mucosal tissue
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
WO2006118948A2 (en) * 2005-04-29 2006-11-09 Cubist Pharmaceuticals, Inc. Therapeutic compositions
CA2635603C (en) * 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
WO2007133807A2 (en) * 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
JP5230613B2 (ja) 2006-05-23 2013-07-10 テラコス・インコーポレイテッド グルコース輸送体阻害剤およびその使用方法
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2063864A4 (de) 2006-09-20 2012-03-14 Monosol Rx Llc Verzehrbare wasserlösliche folie mit einem schäumungsreduzierenden geschmacksmittel
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
AU2008232419B2 (en) 2007-04-02 2013-06-20 Theracos, Inc. Benzylic glycoside derivatives and methods of use
WO2008124634A1 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
JP2010523595A (ja) 2007-04-04 2010-07-15 マサチューセッツ インスティテュート オブ テクノロジー ポリ(アミノ酸)ターゲッティング部分
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP3620153A1 (de) 2007-07-06 2020-03-11 Lupin Limited Pharmazeutische zusammensetzungen zur wirkstoffverabreichung im magen-darm-trakt
PL2187742T3 (pl) 2007-08-23 2018-06-29 Theracos Sub, Llc Pochodne (2s,3r,4r,5s,6r)-2-(4-chloro-3-benzylofenylo)-6-(hydroksymetylo) tetrahydro-2h-pirano-3,4,5-triolu do stosowania w leczeniu cukrzycy
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
AR073118A1 (es) 2008-08-22 2010-10-13 Theracos Inc Procesos para la preparacion de inhibidores de sglt2 y formas cristalinas del mismo.
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US8974826B2 (en) 2010-06-10 2015-03-10 Monosol Rx, Llc Nanoparticle film delivery systems
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012048333A1 (en) 2010-10-08 2012-04-12 R.P. Scherer Technologies, Llc Oral vaccine fast-dissolving dosage form using starch
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
ES2658972T3 (es) 2012-06-20 2018-03-13 University Of Waterloo Sistema de administración de nanopartículas mucoadhesivas
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
US10285915B2 (en) 2012-10-17 2019-05-14 The Procter & Gamble Company Strip for the delivery of an oral care active and methods for applying oral care actives
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3452023A1 (de) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Epinephrinzusammensetzungen mit verbesserter freisetzung
US20200352991A1 (en) * 2017-07-27 2020-11-12 The Trustees Of Columbia University In The City Of New York Polymer films with antimicrobial agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS57110254A (en) * 1980-12-29 1982-07-09 Teijin Ltd Coating agent of injured membrane part of oral cavity
AU565354B2 (en) * 1983-11-14 1987-09-10 Bio-Mimetics Inc. Bioadhesive compositions and methods of treatment therewith
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US4713243A (en) * 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US5196202A (en) * 1986-09-01 1993-03-23 Teikoku Seiyaku Kabushiki Kaisha Sustained release dosage form
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
JPH03504968A (ja) * 1988-04-19 1991-10-31 サウスウェスト・リサーチ・インスティチュート 塩感受性シェル物質を有するカプセルからの活性成分の制御放出
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5077051A (en) * 1990-04-10 1991-12-31 Warner-Lambert Company Sustained release of active agents from bioadhesive microcapsules

Also Published As

Publication number Publication date
DK0516141T3 (da) 1996-09-02
US5472704A (en) 1995-12-05
DE69212710D1 (de) 1996-09-19
ITMI911486A0 (it) 1991-05-30
ITMI911486A1 (it) 1992-11-30
GR3020813T3 (en) 1996-11-30
EP0516141A1 (de) 1992-12-02
EP0516141B1 (de) 1996-08-14
IT1250421B (it) 1995-04-07
ES2091363T3 (es) 1996-11-01
JPH07215843A (ja) 1995-08-15
ATE141159T1 (de) 1996-08-15

Similar Documents

Publication Publication Date Title
ATE141159T1 (de) Pharmazeutische zusammensetzung mit kontrollierter freigabe und bioadhäsiven eigenschaften
GR1002229B (en) Extrudable compositions for topical or transdermal drug delivery.
DE69622980D1 (de) Bioadhäsives Arzneimittel zur kontrollierten Freisetzung von Wirkstoffen
DE69638364D1 (de) Formulierungen mit kontrollierter abgabe (albuterol)
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
ATE225165T1 (de) Im unteren teil des verdauungstrakts freisetzende pharmazeutische zubereitung in form einer beschichteten kapsel
AU7719087A (en) Wound dressing, its preparation and use
NO962833L (no) Transdermalt preparat omfattende polyvinylpyrrolidin
CA2257976A1 (en) Compositions and methods for coating medical devices
GR910100283A (el) Στερεά από του στόματος χορηγουμένη φαρμακευτική μορφή δοσιμετρήσεως προγραμματισμένου ρυ?μού απελευ?ερώσεως.
WO2004010975A3 (en) Controlled drug delivery
CA2039655A1 (en) Sheet for containing micronized powdered medicament
PT923934E (pt) Formulacao de matriz de libertacao modificada de cefaclor e cefalexina
EP0297535A3 (de) Arzneimittel-Verabreichungssystem
EP0161817A3 (de) Urogastrone
CA2012123A1 (en) Transdermal System Exhibiting Graduated Drug Release and its Use for the Local or Systemic Administration of Active Substances
EP0250129A3 (de) Lippenstift für die Verabreichung von Medikamenten
EP0761209A3 (de) Ranitidinformulierungen mit gesteuerter Freisetzung
FR2662160B1 (fr) Derives d'alkylthio-3 propyl-3 benzothiazoline leur preparation et les medicaments les contenant.
CA2481227A1 (en) Adherent n,o-carboxymethylchitosan drug delivery devices for moist tissue and methods of their use
DE50105219D1 (de) Hautfreundliches wirkstoffpflaster zur transdermalen verabreichung ätherischer öle
ATE329577T1 (de) Bismut enthaltende arzneimittel in topischen darreichungsformen
AUPN699395A0 (en) Patient controlled drug delivery device
AU5887796A (en) Patient controlled drug delivery device

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee